The economic consequences of non-evidence-based clopidogrel use

American Heart Journal

Volumn 155, Issue 5, 2008, Pages 904-909

  Choudhry, Niteesh K ^a   Levin, Raisa ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ADULT; ANTICOAGULANT THERAPY; ARTERY DISEASE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG COST; DRUG INDICATION; DRUG USE; ECONOMIC ASPECT; EVIDENCE BASED PRACTICE; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TABLET; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MEDICARE; PENNSYLVANIA; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES; TICLOPIDINE; UNITED STATES; VASCULAR DISEASES;

EID: 42649087091     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.11.039     Document Type: Article

References (39)

1. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
2. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
3. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
4. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
5. Diener H.C., Bogousslavsky J., Brass L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
6. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
7. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
8. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
9. Hendrick B. New survey heightens debate: do prescription drug commercials merely inform? Or do they prompt people to play doctor?. Atlanta J-Constitution (2006)
10. Tricoci P., Roe M.T., Mulgund J., et al. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med 166 (2006) 806-811
11. Choudhry N.K., Soumerai S.B., Normand S.L., et al. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med 119 (2006) 607-615
12. Winkelmayer W.C., Charytan D.M., Levin R., et al. Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. Am J Kidney Dis 47 (2006) 301-308
13. Soumerai S.B., McLaughlin T.J., Spiegelman D., et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 277 (1997) 115-121
14. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
15. Drugstore.com, www.drugstore.com. Accessed January 20, 2007.
16. Commonwealth of Pennsylvania. Pharmaceutical Assistance Contract for the Elderly Act. 62 P.S. 2901-2908. http://www.pacode.com/secure/data/006/006toc.html. Accessed May 16, 2006.
17. Wang P.S., Schneeweiss S., Avorn J., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353 (2005) 2335-2341
18. Solomon D.H., Schneeweiss S., Glynn R.J., et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109 (2004) 2068-2073
19. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 44 (2004) E1-E211
20. U.S. Food and Drug Administration.http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory [Accessed]
21. P.D.R. Thompson. 2005 red book. April 2006 ed.
22. Fischer M.A., and Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less?. JAMA 291 (2004) 1850-1856
23. Schiavino D., Nucera E., Milani A., et al. The aspirin disease. Thorax 55 (2000) 66-69
24. Chan F.K., Ching J.Y., Hung L.C., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352 (2005) 238-244
25. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
26. IMS Health. Leading products by global pharmaceutical sales (2005). http://www.imshealth.com/ims/portal/front/articleC/0%2C2777%2C6599_77478579_77479663%2C00.html [Accessed October 9, 2006]
27. IMS Health. Leading 20 products by U.S. sales (2005). http://www.imshealth.com/ims/portal/front/articleC/0%2C2777%2C6599_73915261_77140545%2C00.html [Accessed October 11, 2006]
28. Reinhardt U.E., Hussey P.S., and Anderson G.F. Cross-national comparisons of health systems using OECD data, 1999. Health Aff 21 (2002) 169-181
29. Schwartz R.K., Soumerai S.B., and Avorn J. Physician motivations for nonscientific drug prescribing. Soc Sci Med 28 (1989) 577-582
30. Avorn J. Powerful medicines: the benefits, risks, and costs of prescription drugs (2004), Knopf, New York 269-271
31. Cockburn J., and Pit S. Prescribing behaviour in clinical practice: patients' expectations and doctors' perceptions of patients' expectations-a questionnaire study. BMJ 315 (1997) 520-523
32. Mintzes B., Barer M.L., Kravitz R.L., et al. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ 324 (2002) 278-279
33. Choudhry N.K., Anderson G.M., Laupacis A., et al. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 332 (2006) 141-145
34. Zachry III W.M., Dalen J.E., and Jackson T.R. Clinicians' responses to direct-to-consumer advertising of prescription medications. Arch Intern Med 163 (2003) 1808-1812
35. Majumdar S.R., McAlister F.A., and Soumerai S.B. Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. Am J Med 115 (2003) 467-472
36. Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006) 1903-1912
37. Hankey G.J., and Eikelboom J.W. Aspirin resistance. Lancet 367 (2006) 606-617
38. Armstrong D. Aspirin dispute is fueled by funds of industry rivals. Wall St J (2006)
39. Wang T.H., Bhatt D.L., and Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27 (2006) 647-654